Opyl Limited (ASX: OPL) a leader in clinical trial design and biostatistical validation, is pleased to announce the signing of a service agreement with Commercial Eyes Pty Ltd, a ProductLife Group company and prominent Australian pharmaceutical and medical device commercialisation company.
Commercial Eyes is a leading lifesciences consultancy that offers full end-to-end commercialisation services. As part of ProductLife Group, an international leader in the life sciences industry, Commercial Eyes has expanded its global presence, enabling broader market access and expertise across the JAPAC region and beyond.
This collaboration will leverage global insights to enhance Commercial Eyes’ market research and competitive intelligence capabilities.
This agreement signifies a major milestone in Opyl’s ongoing commitment to enhancing clinical trial outcomes through AI-driven solutions.
Under the terms of this agreement, Opyl will provide Commercial Eyes with market research, and competitive intelligence analysis to assist in a range of client projects, across the pharmaceutical, medtech and biotechnology sectors.
Key Highlights
- AI-Driven Clinical Trial Information: The service agreement enables Commercial Eyes to utilise Opyl’s TrialKey platform, which provides data-backed recommendations and boasts over 92% accuracy in forecasting clinical trial outcomes.
- Comprehensive Services: The paid partnership covers market research, and competitive intelligence analysis to support Commercial Eyes in offering strategic insights to its clients in the pharmaceutical and medical device sectors.
- International Exposure: Commercial Eyes, as part of the ProductLife Group (PLG), extends Opyl’s reach to international markets, particularly across Europe and the JAPAC region.
- Increased Domestic Exposure: The partnership also increases Opyl’s presence in the
domestic market by leveraging Commercial Eyes’ strong reputation and client base
within the Australian healthcare sector. - Strategic Market Positioning: TrialKey’s data analytics empower Commercial Eyes to
navigate the complex trial landscape, providing their clients with informed, strategic
guidance that enhance commercial positioning and success.
Click here for the full ASX Release
This article includes content from Opyl, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Credit: Source link
